Who can use Cotellic(Cobimetinib)?

Cotellic is indicated for BRAF-mutant unresectable or metastatic melanoma in combination with vemurafenib and as monotherapy for histiocytic neoplasms.

Therapeutic Indications for Cobimetinib

Cobimetinib, a MEK inhibitor, is approved for two distinct adult populations: first, in combination with vemurafenib for treating unresectable or metastatic melanoma harboring a BRAF V600E or V600K mutation, confirmed via FDA-approved testing. Second, it is indicated as a single agent for the treatment of various histiocytic neoplasms, including Erdheim-Chester disease and Langerhans cell histiocytosis.

Related Columns

Cobimetinib(Cotellic)

Cotellic is indicated for the treatment of adult patients with melanoma...

WeChat Scan
Free Inquiry

Indications of Cobimetinib (Cotellic)

Cobimetinib (Cotellic) is a kinase inhibitor that plays an important role in the field of cancer treatment.Indications of Cobimetinib (Cotellic)Melanoma TreatmentCobimetinib, in combination with vemur...

Indications of Cobimetinib

Cobimetinib is an oral medication commonly used to treat adult patients with BRAF V600E or V600K mutations in unresectable or metastatic melanoma. It is usually used in combination with Vemurafenib to...

Cobimetinib (Cotellic):Clinical Uses, Recommended Dosage, Treatment Effect

Cobimetinib (Cotellic) is a therapeutic drug for melanoma with BRAF V600E or V600K mutations, used in combination with Vemurafenib. BRAF V600E or V600K mutations are the most common types of mutations...

Cobimetinib Instructions

Cobimetinib is a targeted therapy drug mainly used to treat unresectable or metastatic melanoma with BRAF V600E/K mutation. The drug is a MEK1/MEK2 inhibitor that inhibits tumor growth by blocking cel...

Cobimetinib targeted drug

Cobimetinib is a targeted therapy drug that blocks the tumor cell proliferation signaling pathway by inhibiting the activity of MEK1/2 protein kinases. It plays an important role in the treatment of u...